Armed with a $47M round, Gates-backed Vis­ter­ra aims at a PhI­Ib flu drug study

At the time Vis­ter­ra made a bid ear­ly this year to go pub­lic, the tim­ing was off. The boom of 2014 was long gone and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.